- Transgenomic (NASDAQ:TBIO) launches two new diagnostic tests for genetic mutations that will enable clinicians to customize therapies for certain cancer patients. The blood tests, for the detection of epidermal growth factor receptor (EGFR) exon T790M and EGFR exon 12 S492R, will be offered as services through the company's CLIA-certified laboratory using its ICE COLD-PCR technology which enables up to a 500-fold increase in sensitivity.
- Patients with these mutations do not respond well to certain cancer drugs.
- Shares are up 43% premarket on robust volume.